OPHLY: AI 评分 54/100 — AI 分析 (4月 2026)

Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company based in Osaka, Japan, focused on the development and commercialization of innovative medicines. The company's portfolio includes treatments for cancer, diabetes, and other specialty diseases.

Key Facts: AI Score: 54/100 Sector: Healthcare

公司概况

概要：

Ono Pharmaceutical Co., Ltd., a Japanese multinational, develops and markets pharmaceutical products and diagnostic reagents globally, with a focus on oncology, diabetes, and specialty areas; the company distinguishes itself through its innovative drug development pipeline and established presence in key therapeutic markets, operating in the competitive healthcare landscape.

OPHLY是做什么的？

Founded in 1717 in Osaka, Japan, Ono Pharmaceutical Co., Ltd. has evolved from a traditional medicine merchant to a global pharmaceutical company. The company's initial focus was on traditional Japanese medicines before transitioning to modern pharmaceuticals. A key turning point was its expansion into research and development, leading to the creation of innovative drugs. Ono Pharmaceutical's portfolio includes a range of products, with a strong emphasis on oncology, diabetes, and specialty areas. Its flagship product, OPDIVO, an intravenous infusion for the treatment of malignant tumors, has achieved significant success in the oncology market. Other key products include GLACTIV and FORXIGA for type 2 diabetes, and ORENCIA injections for rheumatoid arthritis. The company operates globally, with a significant presence in Japan, North America, Europe, and Asia. Ono Pharmaceutical's competitive positioning is based on its commitment to innovation, strategic collaborations, and a focus on unmet medical needs. The company continues to invest in its research and development pipeline, with a focus on developing novel therapies for a range of diseases.

OPHLY的投资论点是什么？

Ono Pharmaceutical Co., Ltd. presents a compelling investment thesis driven by its established presence in key therapeutic areas and a robust pipeline of innovative drugs. The company's oncology franchise, anchored by OPDIVO, continues to be a significant revenue driver. Ono Pharmaceutical's focus on research and development, with a pipeline of potential blockbuster drugs, positions it for long-term growth. The company's financial stability, demonstrated by a profit margin of 12.3% and a dividend yield of 3.38%, provides a solid foundation for future investments. However, investors should be aware of the risks associated with pharmaceutical development, including regulatory hurdles and clinical trial failures. The company's P/E ratio of 17.82 reflects investor expectations for future growth.

OPHLY在哪个行业运营？

Ono Pharmaceutical Co., Ltd. operates in the highly competitive pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The global pharmaceutical market is expected to reach $1.7 trillion by 2027, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Ono Pharmaceutical competes with major pharmaceutical companies, including DSRLF (Daiichi Sankyo), FLMNF (FUJIFILM Holdings), GZPHF (Grifols), HKMPF (Hangzhou Tigermed Consulting), and HKMPY (Hutchison China MediTech), all striving to develop and commercialize innovative therapies. The company's success depends on its ability to navigate the complex regulatory landscape, secure patent protection for its products, and effectively market its drugs to healthcare providers and patients.

Drug Manufacturers - General

Healthcare

OPHLY有哪些增长机遇？

Expansion of OPDIVO into new indications: Ono Pharmaceutical has the opportunity to expand the use of OPDIVO, its flagship oncology product, into new cancer types. The global oncology market is projected to reach $286.6 billion by 2028, providing a significant opportunity for Ono Pharmaceutical to increase its revenue. This expansion requires successful clinical trials and regulatory approvals, but could significantly boost long-term growth.
Development of novel therapies for autoimmune diseases: Ono Pharmaceutical is actively developing new therapies for autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. The market for autoimmune disease treatments is expected to reach $150 billion by 2025, driven by the increasing prevalence of these conditions. Successful development and commercialization of these therapies would diversify Ono Pharmaceutical's product portfolio and expand its market reach.
Strategic collaborations and partnerships: Ono Pharmaceutical can leverage strategic collaborations and partnerships to accelerate its research and development efforts and expand its global presence. Collaborating with other pharmaceutical companies, biotechnology firms, and research institutions can provide access to new technologies, expertise, and markets. These partnerships can help Ono Pharmaceutical to develop and commercialize innovative therapies more efficiently and effectively.
Geographic expansion into emerging markets: Ono Pharmaceutical has the opportunity to expand its presence in emerging markets, such as China, India, and Brazil. These markets are experiencing rapid economic growth and increasing healthcare spending, creating significant opportunities for pharmaceutical companies. Expanding into these markets requires adapting to local regulatory requirements, establishing distribution networks, and building relationships with healthcare providers.
Investment in digital health technologies: Ono Pharmaceutical can invest in digital health technologies, such as telemedicine, remote patient monitoring, and artificial intelligence, to improve patient outcomes and enhance its competitive advantage. These technologies can help to personalize treatment plans, improve medication adherence, and reduce healthcare costs. Integrating digital health technologies into its business model can help Ono Pharmaceutical to differentiate itself from its competitors and attract new customers.

Market capitalization of $6.89 billion, reflecting its established position in the pharmaceutical industry.
P/E ratio of 17.82, indicating investor expectations for future earnings growth.
Profit margin of 12.3%, demonstrating efficient operations and profitability.
Gross margin of 69.8%, showcasing the company's ability to maintain high pricing on its products.
Dividend yield of 3.38%, providing a steady income stream for investors.

OPHLY提供哪些产品和服务？

Develops and commercializes pharmaceutical products.
Produces and sells diagnostic reagents.
Focuses on oncology, diabetes, and specialty therapeutic areas.
Markets OPDIVO for the treatment of malignant tumors.
Offers GLACTIV and FORXIGA for type 2 diabetes.
Provides ORENCIA injections for rheumatoid arthritis.
Conducts research and development to discover new drugs.

OPHLY如何赚钱？

Develops and patents innovative pharmaceutical products.
Conducts clinical trials to demonstrate the safety and efficacy of its drugs.
Obtains regulatory approvals from agencies such as the FDA and EMA.
Manufactures and markets its products globally.
Generates revenue through the sale of its pharmaceutical products and diagnostic reagents.

Hospitals and clinics.
Healthcare providers, including physicians and nurses.
Pharmacies.
Patients with cancer, diabetes, rheumatoid arthritis, and other diseases.
Government healthcare agencies.

Patent protection for its innovative pharmaceutical products.
Strong brand recognition and reputation in the pharmaceutical industry.
Established relationships with healthcare providers and patients.
Extensive research and development capabilities.
Global distribution network.

什么因素可能推动OPHLY股价上涨？

Ongoing: Continued expansion of OPDIVO into new cancer indications, driving revenue growth.
Upcoming: Potential regulatory approvals for new drug candidates in the pipeline, expanding the product portfolio.
Ongoing: Strategic collaborations and partnerships to accelerate research and development efforts.
Upcoming: Geographic expansion into emerging markets, increasing market reach.
Ongoing: Investment in digital health technologies to improve patient outcomes and enhance competitive advantage.

OPHLY的主要风险是什么？

Potential: Increasing competition from other pharmaceutical companies, eroding market share.
Potential: Patent expirations, leading to generic competition and reduced revenue.
Potential: Regulatory changes, impacting drug development and approval processes.
Potential: Economic downturns, reducing healthcare spending and demand for pharmaceutical products.
Ongoing: Risks associated with clinical trial failures and regulatory setbacks.

OPHLY的核心优势是什么？

Innovative drug development pipeline.
Established presence in key therapeutic areas.
Strong financial performance.
Global distribution network.

OPHLY的劣势是什么？

Reliance on a limited number of key products.
Exposure to generic competition.
Dependence on regulatory approvals.
Limited presence in emerging markets.

OPHLY有哪些机遇？

Expansion into new therapeutic areas.
Strategic collaborations and partnerships.
Geographic expansion into emerging markets.
Investment in digital health technologies.

OPHLY面临哪些威胁？

Increasing competition from other pharmaceutical companies.
Patent expirations.
Regulatory changes.
Economic downturns.

OPHLY的竞争对手是谁？

Daiichi Sankyo — Focuses on cardiovascular and oncology drugs. — (DSRLF)
FUJIFILM Holdings — Diversified company with a healthcare segment. — (FLMNF)
Grifols — Specializes in plasma-derived therapies. — (GZPHF)
Hangzhou Tigermed Consulting — Provides clinical research services. — (HKMPF)
Hutchison China MediTech — Focuses on innovative cancer drugs and diagnostics. — (HKMPY)

Key Metrics

MoonshotScore: 54/100

Company Profile

CEO: Gyo Sagara
Headquarters: Osaka, JP
Employees: 3,853
Founded: 2012

AI Insight

AI analysis pending for OPHLY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: OPHL

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Ono Pharmaceutical Co., Ltd. do?

Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. The company's primary focus is on oncology, diabetes, and specialty therapeutic areas. Ono Pharmaceutical's flagship product, OPDIVO, is a leading immunotherapy drug used to treat various types of cancer. The company also offers a range of other pharmaceutical products and diagnostic reagents, serving patients and healthcare providers worldwide. Ono Pharmaceutical is committed to research and development, with a pipeline of potential new drugs in various stages of development.

What do analysts say about OPHLY stock?

Analyst coverage of OPHLY stock is limited due to its OTC listing and ADR Level 1 status. However, analysts generally recognize Ono Pharmaceutical's strong position in the oncology market, driven by OPDIVO. Key valuation metrics include the company's P/E ratio, profit margin, and dividend yield. Growth considerations include the potential for OPDIVO to expand into new indications, the success of its pipeline drugs, and its ability to penetrate emerging markets. Investors should conduct their own research and consider their individual risk tolerance before investing in OPHLY.

What are the main risks for OPHLY?

Ono Pharmaceutical faces several risks, including increasing competition from other pharmaceutical companies, patent expirations, regulatory changes, and economic downturns. The company's reliance on OPDIVO for a significant portion of its revenue makes it vulnerable to competition from other immunotherapy drugs. Patent expirations could lead to generic competition and reduced revenue. Regulatory changes could impact drug development and approval processes. Economic downturns could reduce healthcare spending and demand for pharmaceutical products. Investors should carefully consider these risks before investing in OPHLY.